指南与共识重症综合管理与镇静镇痛消化、代谢与肾脏急症

中国抗真菌药物管理共识(2024版)

Consensus for antifungal stewardship in China (2024 edition).
指南 / 共识 · J Thorac Dis · 2024-06-26
一句话结论中国首部抗真菌药物管理(AFS)共识,经46位专家德尔菲法对24项指标达成共识,其中22项最终同意率≥80%。

该共识针对侵袭性真菌病(IFD)误诊率高、抗真菌药物处方质量低、不良反应发生率高及疾病负担重等问题,基于国际AFS共识推荐的指标、结合中国现状与多领域专家临床经验,筛选出AFS指标,并邀请呼吸、血液、重症监护病房(ICU)、皮肤、感染、微生物实验室和药学领域专家以德尔菲法评估,同意率≥80%视为达成共识。结果共24项指标达成共识,包括正确患者指标4项、正确时机指标3项、正确使用指标17项;正确使用指标细分为药物选择8项、药物剂量4项、药物降阶梯1项、用药疗程2项、药物消耗2项。46位权威专家评估审核后,22项指标最终同意率≥80%。该共识为中国首部AFS共识,也是亚洲首部AFS共识,有助于建立中国AFS标准、指导医院实施AFS、促进抗真菌药物合理使用并改善患者预后。

要点

  • 共识采用德尔菲法,同意率≥80%视为达成共识,46位权威专家参与评估审核。
  • 最终24项AFS指标达成共识:正确患者4项、正确时机3项、正确使用17项。
  • 正确使用指标细分为药物选择8项、药物剂量4项、药物降阶梯1项、用药疗程2项、药物消耗2项。
  • 46位专家评估审核后,22项指标最终同意率≥80%。
  • 该共识为中国首部AFS共识,也是亚洲首部AFS共识,旨在指导医院实施AFS。

适用人群与场景

  • 涉及侵袭性真菌病(IFD)诊疗的医院及临床科室,包括呼吸、血液、重症监护病房(ICU)、皮肤、感染、微生物实验室和药学领域。

诊断标准与关键阈值

  • 德尔菲法共识标准:指标同意率≥80%视为达成共识。

研究设计与关键结果

  • 共识基于国际AFS共识推荐的指标、结合中国现状与多领域权威专家临床经验筛选AFS指标,邀请呼吸、血液、ICU、皮肤、感染、微生物实验室和药学领域专家以德尔菲法评估,同意率≥80%视为达成共识。
  • 共24项指标达成共识:正确患者指标4项、正确时机指标3项、正确使用指标17项。
  • 正确使用指标细分为药物选择8项、药物剂量4项、药物降阶梯1项、用药疗程2项、药物消耗2项。
  • 46位权威专家评估审核后,22项指标最终同意率≥80%。

证据类型、等级与局限

  • 证据类型:共识(德尔菲法)。
  • 共识达成标准:同意率≥80%。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为该共识有助于建立中国AFS标准,指导医院实施AFS,促进抗真菌药物合理使用并改善患者预后。

指南或共识出处

  • 共识名称:中国抗真菌药物管理共识(2024版)(Consensus for antifungal stewardship in China (2024 edition));发表期刊:J Thorac Dis;年份:2024年。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Invasive fungal disease (IFD) has become a serious threat to human health in China and around the world, with high mortality and morbidity. Currently, the misdiagnosis rate of IFD is extremely high, compounded with the low quality of prescription antifungals and the high incidence of adverse events associated with IFD treatment, resulting in lengthy hospitalization, low clinical response, and high disease burden, which have become serious challenges in clinical practice. Antifungal stewardship (AFS) can not only significantly increase the early diagnosis rate of IFD, reduce inappropriate utilization of antifungal drugs, improve patient prognosis, but can also improve therapeutic safety and reduce healthcare expenses. Thus, it is urgent to identify key AFS metrics suitable for China's current situation.

METHODS: Based on metrics recommended by international AFS consensuses, combined with the current situation of China and the clinical experience of authoritative experts in various fields, several metrics were selected, and experts in the fields of respiratory diseases, hematology, intensive care units (ICUs), dermatology, infectious diseases, microbiology laboratory and pharmacy were invited to assess AFS metrics by the Delphi method. Consensus was considered to be reached with an agreement level of ≥80% for the metric.

RESULTS: Consensus was reached for 24 metrics, including right patient metrics (n=4), right time metrics (n=3), and right use metrics (n=17). Right use metrics were further subdivided into drug choice (n=8), drug dosage (n=4), drug de-escalation (n=1), drug duration (n=2), and drug consumption (n=2) metrics. Forty-six authoritative experts assessed and reviewed the above metrics, and a consensus was reached with a final agreement level of ≥80% for 22 metrics.

CONCLUSIONS: This consensus is the first to propose a set of AFS metrics suitable for China, which helps to establish AFS standards in China and is also the first AFS consensus in Asia, and may improve the standard of clinical diagnosis and treatment of IFD, and guide hospitals to implement AFS, ultimately promoting the rational use of antifungal drugs and improving patient prognosis.

来源:J Thorac Dis,查看原文。版权归原作者所有。

参考来源

  1. Ye F, Cai S, Cao B, et al. Consensus for antifungal stewardship in China (2024 edition). J Thorac Dis. 2024. PMID: 38983176. doi:10.21037/jtd-24-13

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。